Latest Regulatory News

CuFe is seeking to take full ownership of its Tennant Creek copper-gold-bismuth project by issuing 1.6 billion shares to the holders of the remaining 45% interest. The deal could simplify development decisions, but would also leave Gold Valley and its associates with about 53% of CuFe if completed.

EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.

Beetaloo Energy is approaching a pivotal Q4 milestone, with its Carpentaria Gas Plant moving into final instrumentation and electrical works after Carpentaria-5H sustained an average 6.9 TJ/day flow. The company also ended September with $113.2 million in liquidity and unveiled a longer-term gas-to-power and data centre opportunity near Darwin.

HUB24’s total funds under administration rose 15% to $168.6 billion in the first quarter, while platform net inflows reached $4.0 billion. Growth remained broad-based across advisers and wealth software, although inflows fell 23% from a strong prior-year comparison.

Wia Gold has emerged from a pivotal quarter with a 1.95Moz Probable Ore Reserve, A$229.2 million in cash and a proposed US$360 million debt facility supporting its Kokoseb development plan. Construction preparations are advancing, but lender approval, definitive financing documents and Namibian permits remain crucial hurdles before early works can begin.

Critical Resources has secured exclusivity to acquire 90% of a 29 km² Suriname exploration project just 4 km from Zijin’s producing Rosebel mine. The strategic land position expands the company’s prospective Suriname portfolio, but the project has no reported exploration results, resources or reserves.

Rox Resources has accelerated underground development and advanced construction at Youanmi, with the processing plant 39% complete and first gold still targeted for mid-2027. The project is now fully permitted and funded facilities have begun drawing, although construction spending and one major contract remain in focus.

Ramsay Health Care’s proposed separation of its 52.79% Ramsay Santé stake has reached a key regulatory milestone, with ASIC registering the Demerger Booklet. Shareholders will vote on the transaction on 24 November, but approval remains only one step in a process that could create two separately traded healthcare exposures.

Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.

Cobalt Blue has signed a non-binding term sheet with Swiss trader STG Metals for cobalt metal from its proposed Kwinana refinery. The proposed deal covers up to 1,000 tonnes a year, but construction, product qualification and a definitive agreement remain outstanding.

Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.

NOVONIX has replaced a binding PowerCo supply agreement covering at least 32,000 tonnes of synthetic graphite with a framework that leaves volume and price unresolved. A new offtake deal will only be negotiated after customer qualification and further certification.